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Background: It is vitally important that there is a connection between health research and clinical practice. Indications
as to the impact of the research on evidence-based practice and policy can be obtained by tracking the use of outputs
of health research, especially its use in clinical guidelines (CGs). This study aims to assess the proportion of National
Institute for Health and Care Excellence (NICE) CGs citing National Institute for Health Research Health Technology
Assessment (NIHR HTA) studies and the impact of evidence from those studies on the included NICE CGs.
Methods: This is a retrospective cohort study assessing the proportion of NICE CGs from all NICE CGs issued between
April 2001 and April 2012, which cited evidence from studies funded by the NIHR HTA Programme and the impact of
those studies on the CGs as the primary and secondary outcome measures.
Results: Of the cohort of NICE CGs (n = 122), 3 (2%) CGs were based on previous NIHR HTA reports and would not
have been issued in that form without those NIHR HTA studies, 90 (74%) included evidence from NIHR HTA studies,
and 29 (24%) did not include evidence from NIHR HTA studies. The impact of NIHR HTA evidence on NICE CGs varied
in the type and quantity of data used.
Conclusions: Findings suggest that NIHR HTA funded research impacts on clinical guidance from NICE and hence is
well connected to both clinical practice and policy.
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It is vitally important that there is a connection between
health research and clinical practice [1‐3]. It is also of great
importance to research funders to assess the impact of the
research they fund on clinical practice and policy. The
National Institute for Health and Care Excellence [4]
(NICE) publishes several types of publication [4], including
clinical guidelines (CGs) which recommend appropriate
treatment and care for people with specific conditions or
diseases. The organisation has developed an international
reputation, its guidance frequently being consulted (as
judged by high numbers of visits to the website) or adopted
by those in other countries [5]. The recommendations in
NICE CGs are prepared by groups of experts (clinicians, lay* Correspondence: s.turner@soton.ac.uk
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article, unless otherwise stated.members, and patients) who examine the available evi-
dence on particular diseases or clinical areas. The evi-
dence used may include systematic reviews, technology
assessment reports, and findings from clinical trials,
and is moderated by the clinical and patient experience
of members of the guideline groups. Use of this evi-
dence exemplifies the concept of evidence-based prac-
tice and aims to encourage practitioners to employ
similar high standards of care [6].
The National Institute for Health Research Health
Technology Assessment (NIHR HTA) Programme [7]
produces independent research information about the
effectiveness, costs, and broader impact of healthcare
treatments and tests, for those who plan, provide, or
receive care in the National Health Service (NHS). As
part of the NIHR journals library [8], each NIHR HTA
funded project publishes an open access report in the
NIHR journal Health Technology Assessment [9]. Thisle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Impact of NIHR HTA evidence on NICE Clinical
Guidelines (CGs)
Category Criteria
1 CG based on the updating of previous
NIHR HTA journal publication or publication(s)
2 CG drew on the evidence from previously
published NIHR HTA funded studies. Criteria included:
i) NIHR HTA study reviewed in detail
ii) Table(s) taken from the NIHR HTA study
and reproduced in CG
iii) CG drew on NIHR HTA evidence for one
or more sections of the CG
3 No NIHR HTA studies were cited
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freely available online via the NIHR journals library
website [8]. Additionally, researchers funded by NIHR
HTA are also strongly encouraged to disseminate their
findings through other peer reviewed journals [10] and
non-academic routes aimed at both professional com-
munities and the general public. Research funded by the
NIHR HTA programme includes primary research, sys-
tematic reviews, evidence syntheses, and technology as-
sessment reports, and acts as a bridge between evidence
and policymaking, providing NICE with accessible and
evidence-based information to guide their decisions. Con-
versely, the NIHR HTA programme uses knowledge gaps
identified by NICE to inform areas of future research. It
should be noted, however, that the two organisations are
separate and each operates independently of the other.
It is extremely useful and important to track the out-
put of health research [11,12], especially its use in clin-
ical guidelines [13‐15]. There has been much debate
about how the impact of research may be defined or
measured [16,17]. Citation in clinical guidelines can
provide a broad indication that the research has been in-
cluded and therefore has made a contribution, and so
may be considered as having had impact on policy and
evidence-based practice [14]. It is widely recognised that
an important element of impact of research is influence
on policymakers and clinical guidelines [15], and it is
important for research funders to know the degree to
which their funded research is used in order to help
shape future funding strategies.
A study undertaken by Alderson and Tan in 2011 [18] in-
vestigated the number of Cochrane Reviews cited in NICE
CGs and found that 81% of NICE CGs cited these, but that
not all Cochrane Review Groups were represented in the
reviews cited. Similarly, this study seeks to investigate the
number of NICE CGs citing NIHR HTA funded studies
and to assess the impact of those studies on NICE CGs.
Methods
Phase 1
We identified all NICE CGs issued between April 2001
and April 2012 through an online search of the NICE
website [4]. We excluded all CGs which had been with-
drawn or superseded by subsequent CGs. The reference
section for each included NICE CG (including appendi-
ces if they contained reference sections) was independ-
ently searched by two reviewers (ST and SB) to identify
NIHR HTA research cited. Search terms used to identify
NIHR HTA research included ‘HTA’, ‘Health Technol
Assess’, ‘Health Technology Assessment’, ‘NCCHTA’, and
‘technology appraisal’. We defined NIHR HTA research
outputs as publications in the NIHR HTA journal or
other peer reviewed publications arising from projects
funded by the NIHR HTA. Investigators funded byNIHR HTA are required to inform the funders of all
output from their projects, including articles in peer
reviewed journals (other than publications in the NIHR
journals library). Notifications of these publications are
recorded in an internal database. We identified peer
reviewed journal publications arising from NIHR HTA
funded studies by searching this internal database and
matched these titles to citations in the CGs. However,
not all investigators inform the NIHR HTA when they
publish peer reviewed articles, so we also searched the
reference sections of the CGs using author names and
key words from relevant NIHR journals, and checked
articles identified for information as to which organisa-
tion had funded the study, recording those funded by
NIHR HTA. We then calculated the percentage of NICE
CGs citing NIHR HTA funded studies.Phase 2
In the second phase of this study we classified the co-
hort of NICE CGs according to the extent to which they
were influenced by NIHR HTA studies using the criteria
described in Table 1. Category 1 included CGs which
were based on a previous NIHR HTA journal publica-
tion(s) and could not have been issued in the current
form in absence of evidence from the NIHR HTA
study(s). Category 2 included CGs which either reviewed
NIHR HTA study(s) in detail, reproduced evidence ta-
ble(s) from NIHR HTA study(s), or had one or more
sections drawing evidence from NIHR HTA study(s). Ex-
amples which clarify the categorisations are given in the
results section. Category 3 included all the CGs where
no NIHR HTA study(s) were cited.
Assessment of the level of impact was performed inde-
pendently by two researchers (ST and SB). Where there
was disagreement, consensus was reached in consult-
ation with a third researcher (AC). The agreement be-
tween the two researchers was assessed using a Cohen’s
Kappa score.
Table 2 Impact of NIHR HTA funded studies on NICE CGs
Category Number of CGs Percentage
1 3 2%
2 90 74%
3 29 24%
Total 122
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Phase 1
We identified a total of 122 NICE CGs issued between
April 2001 and April 2012. Of these, 93 (76%) had refer-
enced NIHR HTA funded studies (Table 2). We found
inconsistency in the referencing style of the NIHR HTA
journal publications making it difficult to accurately rec-
ord all NIHR HTA journal publications cited. In order
to identify peer reviewed articles cited in CGs we used
an internal Evaluation, Trials and Studies Coordinating
Centre (NETSCC) database which relies on the re-
searchers informing the NIHR HTA programme when
their articles are accepted for publication. We know that
this does not always happen, so it is very likely that is an
underestimation of the number of studies cited.
The total number of citations identified was 321. Of
these, 284 were publications from the NIHR HTA journal
series and 37 were publications in other peer reviewed
journals, of which 5 were not in the NETSCC database
and were identified by searching authors’ names and key-
words. We were unable to identify any citations in 29 out
of the 122 CGs. Figure 1 shows the numbers of citationsFigure 1 Number of publications cited in NICE Clinical Guidelines.of publications in the NIHR HTA journal and other publi-
cations in the CGs within the cohort.
Phase 2
We assessed the impact on NICE CGs of NIHR HTA
evidence and found that, of the 122 CGs, 3 (2%; CGs 7,
19, and 29) were included in category 1; 90 (74%) in cat-
egory 2; and 29 (24%) in category 3 (Table 3). Agreement
between the two researchers assessing impact was high
(Kappa score = 0.980; weighted Kappa score = 0.980).
Between the two researchers there was only disagree-
ment over one CG, which was referred to the third re-
searcher, and was then placed in category 2.
In category 1, the CG was largely based on a previ-
ously published NIHR HTA journal publication or publi-
cations. For example, text in CG7 states that “In April
2001, an HTA review was published on pressure-relieving
devices for the prevention and treatment of pressure
ulcers” [19]. This review updated the earlier Cochrane
systematic review, “Beds, mattresses and cushions for
pressure sore prevention and treatment”. For the pur-
poses of this guideline, the HTA review by Cullum et al.
[19] was then updated by the Cochrane Wounds Group
and National Collaborating Centre for Nursing and Sup-
portive Care staff to provide the most up-to-date and
rigorous source of clinical effectiveness evidence. For
CG19, the methods used included “Systematic review of
the literature – to ‘update’ the previous Health Technol-
ogy Assessment review on the clinical effectiveness and
cost-effectiveness of routine dental checks” [20].
Table 3 Impact of NIHR HTA studies on NICE Clinical Guidelines (CGs)
Category Criteria CGs Total (%)
1 CG based on the
updating of previous
NIHR HTA journal(s)
CG7, CG19, CG29 3 (2%)
2 CG drew on the
evidence from
previously
published NIHR
HTA funded studies
CG3, 8,9 10,11, 15,16, 17, 21, 25, 26, 27, 28, 30, 31, 32, 35, 36, 37, 38, 39, 42, 43, 44, 45, 47, 48, 49, 51,
52, 53, 54, 57, 58, 59, 61, 62, 63, 65, 66, 67, 68, 71, 72, 73, 74, 76, 77, 78, 79, 80, 81, 82, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 101, 102, 103, 105, 106, 107, 108, 109, 113, 117, 121, 122, 123, 124,
126, 127, 131, 132, 133, 135, 136, 137, 138, 139
90 (74%)
3 No NIHR HTA studies
were cited
CG41, 50, 55, 56, 60, 64, 69, 70, 75, 83, 84, 98, 99, 100, 104, 110, 111, 112, 114, 115, 116, 118, 119, 120,
125, 128, 129, 130, 134
29 (24%)
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on NICE CGs varied in the type and quantity of data
used. The guideline could include a large volume of text
about a particular study or studies; one or more tables of
data; or contribute to meta-analysis. The evidence in-
cluded may influence one particular section of the CG
or relate to the whole CG. For example, in CG 95 [21]
(Chest Pain of Recent Onset) the chapter on people pre-
senting with acute chest pain was heavily influenced by
NIHR HTA studies, tables of data from the original
NIHR HTA sources were presented in the CG. In other
cases, such as CG 137 [22] (The epilepsies), evidence from
the SANAD trial [23] was used extensively throughout the
CG, similarly in CG 108 [24] (Chronic Heart Failure) a
systematic review funded by the NIHR HTA programme
[25] provided data which had substantial impact on the
CG as a whole. Initially we had planned to achieve a
greater level of granularity, breaking down the data on im-
pact into more categories; however, we found the ways in
which the data was used by NICE was so heterogeneous
(use of text, tables, trial data, meta-analyses in varying
amounts and combinations) that this couldn’t be done.
We therefore decided to include only 3 categories as de-
scribed in Table 1, amalgamating the heterogeneous data
into category 2.
Discussion
This study assessed the percentage of NICE CGs in-
formed by NIHR HTA studies and the impact of evi-
dence from those studies on the included NICE CGs.
The results show that NIHR HTA funded studies were
referenced in 76% of NICE CGs and had an impact on
76% of the 122 NICE CGs. The study suggests that
NIHR HTA research has a considerable contribution to-
wards NICE CGs, and hence is well connected to both
clinical practice and policy. Demonstrating or quantify-
ing impact of health research is a complex issue [26] and
not all the factors involved are readily quantifiable [16];
however, citation of health research studies in clinical
guidelines has previously been used as an indicator ofimpact [15]. In this study, we found great heterogeneity
in the way NIHR HTA evidence is used by NICE in
CGs. Trying to quantify the impact of the different sce-
narios is both challenging and subjective.
It might be asked why NIHR HTA studies are not ref-
erenced in all CGs. It would be surprising, however, if
there were a complete overlap in these portfolios as the
remits of the NIHR HTA Programme and NICE are
different. Both organisations were set up to support the
NHS and patients in clinical decision-making – either
by identifying important tractable research questions
and hence filling evidence gaps (the NIHR HTA
Programme) or by identifying areas of clinical uncer-
tainty or inconsistency, and producing guidelines based
on (among other things) available evidence to aid clinical
decision-making (NICE). NICE commonly produces
guidelines in areas where clinical practice is variable but
the evidence base is clear. Once the evidence base has
been established, the NIHR HTA Programme, by com-
parison, would not have so much to contribute in an
area such as this. The NIHR HTA Programme will com-
mission research in clinical areas which NICE may
consider too small to devote the resources required to
produce a guideline, but where there is clinical uncer-
tainty resulting in possible sub-optimal patient care. A
similar study conducted by Alderson and Tan [18] found
that some Cochrane Review Groups did not have any
Cochrane reviews cited by NICE CGs. It should also be
remembered that the NICE guideline programme is not
the NIHR HTA Programme’s only customer. NIHR HTA
commissions work informed by research suggestions, and
direct requests from other areas of NICE (such as the Inter-
ventional Procedures Advisory Committee) and other na-
tional bodies (such as the National Screening Committee).
The strengths of this study include its consideration
of data over a long period of time, of more than 10
years, and its comparison of data from a major UK re-
search funder with data from an organisation with an
international reputation responsible for issuing na-
tional guidelines. Thus, this study gives an insight into
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search which has been funded by the NIHR HTA
Programme.
The limitations of this study include the time-limited
nature of CGs, given that this is a snapshot view and
some of the cohort considered herein have already been su-
perseded, as well as the problem of accurately identifying
all NIHR HTA sources used by NICE. NIHR HTA journal
publications were not always cited in a consistent referen-
cing style so we may have failed to identify some of these in
the searches of the reference lists of CGs. Further, also we
know that the data from our internal database used to iden-
tify other peer reviewed publications of NIHR HTA studies
is incomplete. Additionally, this study does not include
NIHR HTA studies which have been published after the
relevant CG was issued; therefore, the contribution of
NIHR HTA funded research to relevant clinical areas will
have been underestimated.
This discussion of the interaction between the NIHR
HTA Programme and NICE’s guidelines has, however,
neglected the final common pathway. The NIHR HTA
Programme strives to provide the NHS with the best
possible evidence. NICE strives to provide it with the
best possible guidance. We can see from this study that
the interactions of these processes seem to work. What
is missing is information on how new evidence or guid-
ance [1,2,15,27,28] impacts on patient care and what
factors influence the implementation of CGs [29‐32].
These relationships are not nearly so well understood
and could be rich areas for future research. Additionally,
the information from NICE has enabled us to assess
how many publications were consulted in the prepar-
ation of the CGs; what we do not know is how this
information was used in the guideline development
process and what it was about the research that was
most valued. It would be most informative to conduct
qualitative research investigating the process of evidence
use in guideline development.
Conclusions
It is vitally important that there is a connection between
health research and clinical practice and it is important
to track the output of health research, especially its use
in clinical guidelines. More than 75% of NICE CGs is-
sued between April 2001 and April 2012 utilised evi-
dence from NIHR HTA funded research. Findings
suggest that evidence from NIHR HTA funded research
impacts on NICE CGs and hence is well connected to
both clinical practice and policy.
Abbreviations
CG: Clinical guideline; HTA: Health technology assessment;
NETSCC: Evaluation, Trials and Studies Coordinating Centre; NHS: National
Health Service; NICE: National Institute for Health and Care Excellence;
NIHR: National Institute for Health Research.Competing interests
The authors have no competing financial interests; however, all of the
authors are employed by the University of Southampton to work at least
part time for NETSCC and NETSCC’s reputation rests substantially on having
managed the HTA Programme for the Department of Health for over 15
years. AC has worked for the HTA Programme since 2005; ST worked for the
HTA Programme from 2005 to 2008.
Authors’ contributions
The study was conceived and designed by SB, AC, and ST, and undertaken
by SB and ST with advice from AC; ST led the writing guided by AC and SB.
All authors read and approved the final manuscript.
Funding statement
This research was supported by the NIHR Evaluation, Trials and Studies
Coordinating Centre (NETSCC) through its Research on Research programme.
The views and opinions expressed are those of the authors and do not
necessarily reflect those of the Department of Health, or of NETSCC.
Study approval
This study did not require study ethics approval; it did not involve patients
or clinical data.
Author details
1National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre (NETSCC), University of Southampton, Alpha House,
Enterprise Road, Southampton SO16 7NS, UK. 2University of Southampton,
Wessex Institute and University Hospital Southampton NHS Foundation Trust,
University of Southampton, Alpha House, Enterprise Road, Southampton
SO16 7NS, UK.
Received: 10 March 2015 Accepted: 21 July 2015
References
1. Boaz A, Baeza J, Fraser A. Effective implementation of research into practice:
an overview of systematic reviews of the health literature. BMC Res Notes.
2011;4:212.
2. Holmes B, Scarrow G, Schellenberg M. Translating evidence into practice:
the role of health research funders. Implement Sci. 2012;7:39. doi:10.1186/
1748-5908-7-39.
3. Lewison G, Sullivan R. The impact of cancer research: how publications
influence UK cancer clinical guidelines. Br J Cancer. 2008;98:1944–50.
4. National Institute for Health and Care Excellence. http://www.nice.org.uk/.
Accessed February 2014.
5. Rawlins MD. The decade of NICE. Lancet. 2013;374:351–2.
6. Rawlins MD. NICE work – providing guidance to the British National Health
Service. N Engl J Med. 2004;351:1383–5.
7. NIHR Health Technology Assessment Programme. http://
www.nets.nihr.ac.uk/programmes/hta. Accessed February 2014.
8. NIHR Journals Library. http://www.journalslibrary.nihr.ac.uk/hta. Accessed
July 2015.
9. Turner S, Wright D, Maeso R, Cook A, Milne R. Publication rate for funded
studies from a major UK health research funder: a cohort study. BMJ Open.
2013;3:e002521.
10. Wright D, Young A, Iserman E, Maeso R, Turner S, Haynes RB, et al. The
clinical relevance and newsworthiness of NIHR HTA-funded research: a
cohort study. BMJ Open. 2014;4, e004556.
11. Hanney S, Frame I, Grant J, Buxton M, Young T, Lewison G. Using
categorisations of citations when assessing the outcomes from health
research. Scientometrics. 2005;65:357–79.
12. Jones TH, Donovan C, Hanney S. Tracing the wider impacts of biomedical
research: a literature search to develop a novel citation categorisation
technique. Scientometrics. 2012;93:125–34.
13. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing
the gap between research and practice: an overview of systematic reviews
of interventions to promote the implementation of research findings: the
Cochrane Effective Practice and Organization of Care Review Group. BMJ.
1998;317:468.
Turner et al. Health Research Policy and Systems  (2015) 13:37 Page 6 of 614. Grant J, Cottrell R, Cluzeau F, Fawcett G. Evaluating “payback” on biomedical
research from papers cited in clinical guidelines: applied bibliometric study.
BMJ. 2000;320:1107–11.
15. Kryl D, Allen L, Dolby K, Sherbon B, Viney I. Tracking the impact of research
on policy and practice: investigating the feasibility of using citations in
clinical guidelines for research evaluation. BMJ Open. 2012;2, e000897.
16. Sarli CC, Dubinsky EK, Holmes KL. Beyond citation analysis: a model for
assessment of research impact. J Med Libr Assoc. 2010;98:17–23.
17. Moscone F, Tosetti E, Costantini M, Ali M. The impact of scientific research
on health care: evidence from the OECD countries. Econ Model.
2013;32:325–32.
18. Alderson P, Tan T. Use of Cochrane Reviews in NICE clinical guidelines.
Cochrane Database Syst Rev. 2011;12, ED000032.
19. Callum N, Nelson EA, Fleming K, Sheldon T. Systematic reviews of wound
care management: (5) beds; (6) compression; (7) laser therapy, therapeutic
ultrasound, electrotherapy and electromagnetic therapy. Health Technol
Assess. 2001;5:1–221.
20. Davenport C, Elley K, Salas C, Taylor-Weetman CL, Fry-Smith A, Bryan S, et al.
The clinical effectiveness and cost-effectiveness of routine dental checks: a
systematic review and economic evaluation. Health Technol Assess.
2014;7:1–127.
21. NICE. Chest pain of recent onset: Assessment and diagnosis of recent onset
chest pain or discomfort of suspected cardiac origin. NICE clinical guideline
95. Available at www.nice.org.uk/guidance/cg95. 2010.
22. The epilepsies: the diagnosis and management of the epilepsies in adults
and children in primary and secondary care. NICE clinical guideline 137.
Available at www.nice.org.uk/guidance/cg137. 2012.
23. Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, et al.
A randomised controlled trial examining the longer-term outcomes of
standard versus new antiepileptic drugs The SANAD trial. Health Technol
Assess. 2007;11:1–134.
24. Chronic heart failure: Management of chronic heart failure in adults in
primary and secondary care. NICE clinical guideline 108. Available at
www.nice.org.uk/guidance/cg108. 2010.
25. Mant J, Doust JA, Roalfe AK, Barton P, Cowie MR, Glasziou P, et al.
Systematic Review and Individual Patient Data meta-Analysis of Diagnosis of
Heart Failure, with Modelling of Implications of Different Diagnostic
strategies in Primary Care. Health Technology Assessment 2009, 13.
26. Milat AJ, Bauman AE, Redman S. A narrative review of research impact
assessment models and methods. Health Res Policy Syst. 2015;13:18.
doi:10.1186/s12961-015-0003-1.
27. Green LA, Seifert CM. Translation of research into practice: why we can’t
“just do it”. J Am Board Fam Med. 2005;18:541–5.
28. Dougherty M. Clinical guidance. Where NICE leads, can commissioners
follow? Health Serv J. 2008;21:16–7.
29. Francke AL, Smit MC, de Veer AJ, Mistiaen P. Factors influencing the
implementation of clinical guidelines for health care professionals: a
systematic meta-review. BMC Med Inform Decis Mak. 2008;12:38.
doi:10.1186/1472-6947-8-38.
30. Grol R, Grimshaw J. From best evidence to best practice: effective
implementation of change in patients’ care. Lancet. 2003;362:1225–30.
31. Ploeg J, Davies B, Edwards N, Gifford W, Miller PE. Factors influencing best-
practice guideline implementation: lessons learned from administrators,
nursing staff, and project leaders. Worldviews Evid Based Nurs. 2007;4:210–9.
32. Cotter D, Thamer M, Narasimhan K, Zhang Y, Bullock K. Translating epoetin
research into practice: the role of government and the use of scientific
evidence. Health Aff. 2013;25:1249–59.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
